Verona Pharma names new CFO
This article was originally published in Scrip
Executive Summary
London-based Verona Pharma, which develops treatments for respiratory diseases, has named Richard Bungay chief financial officer – effective 5 September 2013. Mr Bungay is also part-time CEO of Chroma Therapeutics, a venture capital-backed biotechnology company developing novel small molecules for inflammation and oncology. He succeeds Danny Lowe in the position. Mr Lowe, who is based in Canada, will continue to work with Mr Bungay for an interim handover period.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.